Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
03:56pm, Wednesday, 23'rd Nov 2022 Benzinga
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday.
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
01:58pm, Wednesday, 23'rd Nov 2022 Benzinga
Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Burlington shares fell 0.1% to
What 7 Analyst Ratings Have To Say About Macrogenics
01:02pm, Wednesday, 23'rd Nov 2022 Benzinga
Within the last quarter, Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
1
1
0
0
Last 30D
Where Macrogenics Stands With Analysts
12:03pm, Wednesday, 23'rd Nov 2022 Benzinga
Over the past 3 months, 7 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a com
Dow Jumps Over 300 Points; S&P 500 Rises 1%
07:23pm, Tuesday, 22'nd Nov 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Tuesday.
The Dow traded up 0.96% to 34,024.49 while the NASDAQ rose 0.79% to 11,111.79. The S&P
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
06:16pm, Tuesday, 22'nd Nov 2022 Benzinga
Gainers
Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel fu
Crude Oil Surges 2%; Best Buy Posts Upbeat Earnings
05:40pm, Tuesday, 22'nd Nov 2022 Benzinga
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 250 points on Tuesday.
The Dow traded up 0.83% to 33,981.56 while the NASDAQ rose 0.37% to 11,065.13. The S&P 500
Why Shares of MacroGenics Were Dropping Tuesday
04:55pm, Tuesday, 22'nd Nov 2022 The Motley Fool
Profit-taking and an analyst downgrade affected the stock's price.
US Stocks Open Higher As Dow Surges 250 Points
03:35pm, Tuesday, 22'nd Nov 2022 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.77% to 33,958.82 while the NASDAQ rose 0.26%
Why Shares of MacroGenics Were Dropping Tuesday
11:55am, Tuesday, 22'nd Nov 2022
Profit-taking and an analyst downgrade affected the stock's price.
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
03:15pm, Friday, 18'th Nov 2022 Zacks Investment Research
Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.
Zacks.com featured highlights MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson
01:39pm, Friday, 18'th Nov 2022 Zacks Investment Research
MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson have been highlighted in this Screen of The Week article.
Gap, Palo Alto Networks And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:11am, Friday, 18'th Nov 2022 Benzinga
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
IVERIC bio, Inc. (NASDAQ: ISEE) shares jumped 20.9% to $20.84 in pre-m
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
11:10pm, Thursday, 17'th Nov 2022 GlobeNewswire Inc.
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for
Wall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to Trade
02:55pm, Thursday, 17'th Nov 2022 Zacks Investment Research
The consensus price target hints at a 122.6% upside potential for MacroGenics (MGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
